September 27, 2011
Sosei Group Corporation announced on September 27 that NVA237 (glycopyrronium bromide), a long-acting muscarinic antagonist (LAMA) being investigated for the treatment of chronic obstructive pulmonary disease (COPD), has been filed by Novartis AG for marketing authorization with the European Medicines...read more